Furthermore, information related to cannabis for medical purposes, standards and analytical methods were extracted from German, Swiss and US pharmacopoeias
Dose escalation is critical for managing potential gastrointestinal side effects, which are common with this class of peptides
Gao L, Huang H, Zhang L, Zhang N, Fu Y, Zhu D, et al
one found an overall relative risk of 1.31, and the second an odds ratio of 1.23
Common Mistakes That Increase Risk There are several patterns that may increase the likelihood of muscle loss during GLP-1 treatment: Consistently low protein intake Skipping meals without prioritizing nutrient density Avoiding resistance training Performing excessive cardiovascular exercise without strength work Losing weight rapidly without medical oversight It is also important to monitor side effects that interfere with adequate nutrition
It's important to note that Wegovy (semaglutide 2.4 mg) and Zepbound (tirzepatide) are FDA-approved for chronic weight management, while Ozempic (semaglutide) and Mounjaro (tirzepatide) are approved for type 2 diabetes management, though sometimes used off-label for weight loss
